Table 3.
Serious adverse events
| Adverse events | Number of events | Events/100 patient-years |
|---|---|---|
| Total | 16 | 9.12 |
| Injection site reactionsa | 3 | 1.71 |
| Interstitial pneumonitis | 2 | 1.14 |
| Pneumocystis jiroveci pneumonia | 1 | 0.57 |
| Pneumonia | 1 | 0.57 |
| Miliary tuberculosis | 1 | 0.57 |
| Nontuberculous mycobacteriosis | 1 | 0.57 |
| Cellulitis | 1 | 0.57 |
| Malignant lymphoma | 1 | 0.57 |
| Lymphoproliferative disorder | 1 | 0.57 |
| Perforated colon diverticulum | 1 | 0.57 |
| Generalized rash | 1 | 0.57 |
| Generalized urticaria | 1 | 0.57 |
| Left fibula fracture | 1 | 0.57 |
Serious adverse events as judged by the attending physicians
aInjection site reactions include erythema, itching, hemorrhage, pain, and swelling